摘要
随着纳米技术与RNA干扰(RNA interference,RNAi)技术的发展,纳米载体(nanocarriers,NCS)作为一类新型的基因与药物共载载体在癌症治疗中的应用潜能逐渐彰显,特别是在多药耐药(multidurg-resistance,MDR)肿瘤研究领域。NCS共载基因与化疗药物联合治疗癌症,相对传统化疗,该方法可以减少化疗药物的使用剂量,增加药物在靶器官的分布量,以达到减轻毒副作用及提高疗效的目的。因此在未来癌症治疗中,特别在MDR的临床治疗中,NCS共载基因与化疗药物联合治疗递送体系将产生重要作用。
Current trends in nanotechnology and RNA interference technology have made the application of nanocarriers （NCS） as a novel gene and drug delivery systems very promising for the field of multidrug resistance （MDR） cancer treatment. Co-delivery of gene and chemotherapy drugs with NCS has a good synergistic effect compared with the traditional chemotherapy which can increase the amount of the drug distribution in target organ in order to reduce the toxic side effects thereby enhancing efficacy. Therefore, the advent of co-delivery systems with NCS especiatly in the clinical treatment of MDR has had a significant impact on the cancer treatment.
出处
《药学学报》
CAS
CSCD
北大核心
2013年第7期1091-1098,共8页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(31170939
51103049
81171471)
福建省自然科学基金资助项目(2010J05027
2011J01223)
关键词
纳米载体
基因
化疗药物
共载
肿瘤治疗
nanocarrler
gene
cnemotnerapy arug
co-aellvery
cancer merapy
